Night highlights the medical advice of proper management of type 2 diabetes

the Diabetic It is a decisive issue that does not always get enough attention. Nearly 150 years ago, Night He was a pioneer in creating diabetes treatments, as it turned scientific progress in solutions that improve life. As a reference in the treatment of this condition, Lily launches a campaign of social responsibility and health education called “the Diabetic It is news. To emphasize the importance of consulting a doctor when evaluating the most advanced treatments for the disease.

In Lilly, innovation is our responsibility and is the key to transforming lives, and with a steady moral commitment, we work with medical societies and strategic allies to provide reliable information and health education, as part of our social responsibility.

Diabetes is news: a new course for type 2 diabetes in Mexico

With all progress, Lily focuses on offering treatment options The applicant who converts the management of diabetes and improves the quality of the life of those who need it more. Control of blood sugar levels and weight reduction is very important for adults with type 2 diabetes, because they determine the factors in disease management. the Medical progress They allowed the development of new therapeutic options, providing millions of Mexicans better alternatives to improve their condition and the quality of their lives.

ThyzepatOne of the latest night developments in a new therapeutic category that represents a milestone in the treatment of type 2 diabetes. Patients help to achieve their goals and improve their clinical results, in addition to reducing the risk of serious complications such as myocardial infarction, heart failure, brain infarction, renal damage and diabetic retinopathy.

During the annual conference from American Diabetes Association In June 2023, the results of the wound -2 clinical study were presented, which valued the effectiveness of the Terzopatida against the domaida. The data showed that a night treatment has achieved a greater decrease in blood sugar levels and body weight, from start to 40 weeks of treatment. In addition, more than the weakness of the participants who treated this treatment has reached effective results without experimenting with clinical blood sugar, in relation to patients treated with the competitor.

Type 2 diabetes is a chronic disease Which affects 18.4 % of adults in Mexico, according to the National Health and Nutrition Survey 2023, and represents a large economic burden for the country. In 2022, IMSS reported an account of more than 50,000 million peso in its attention, including indirect costs, such as loss of productivity.

“In more than a century, we have made great progress, including creating a new category of medicines for type 2 diabetes, the first in more than 10 years. But we continue. As this situation grows worldwide, it is necessary to turn attention and provide access to the correct type, in addition to active information, as well as reliable and strong information. Life.”

Commitment to public health in Mexico: Legitimacy and Security in providing treatments

he A new night treatment for type 2 diabetes It reaches Mexico in the road coordination, ensuring quality and efficiency. Extractable solutions are equally effective such as oral and insulin medications (American Diabetes Association, 2023). In addition, the multi -dimensional approach includes education and psychological support necessary, as it can improve emotion well and Patient adhesion. This information is just guidelines and does not replace professional medical advice.

Los Patients should avoid self -tastes, Acquiring medicine in accredited pharmacies and requests its application only in health centers that have health statements. Lilly is the head of health registration and is the only distributor currently authorized, which is important for his knowledge, because its availability outside these channels can offer the safety and effectiveness of treatment.

This treatment is available in more than 15 countries. Lily works alongside the authorities to ensure their authenticity. Dr. Posada said: “Falsification of medicines is a crime of exposing public health, and unauthorized use outside its main index is not clinically support.”

Lilly Mexico invites the population to be informed through the “Diabets Is News” campaign, making enlightened decisions, improving their health, and encouraging the medical community to consult www.lillylatam.com To learn more details about this innovation to treat type 2 diabetes, as well as consult National Register of Clinical Experiences (RNEC), There is additional information about the exceeding clinical trials that were conducted in our country.

About night

Lilly is a drug development company and turns science into health to improve people’s lives in the world. We have been pioneers in the discoveries that changed life for nearly 150 years, and our medications are currently helping more than 51 million people on this planet. By taking advantage of the strength of biotechnology, chemistry and genetic medicine, our scientists quickly promote new discoveries to solve some of the most important health challenges in the world: redefining the care of diabetics and reducing its long -term effects in the long run; Introduction to combating Alzheimer’s disease; Provide solutions to some weak immune system disorders; And treat the most difficult cancer in a more management way. With each step towards a healthier planet, which mainly motivates us to improve the lives of millions of people. This includes conducting innovative clinical trials that reflect the diversity of our world and work to ensure that our drugs are available at reasonable prices. For more information, please visit Lilly.com/latam or Lilly.com. Follow us on Facebook (Lillylatam), LinkedIn (Lillylatam) and Instagram (Lilly_latam).

About exceeding 2 and the transcendent clinical trial program

Over 2 (NCT03987919) 40 weeks, study, Multi -centers, random and open, evaluates the effectiveness and integrity of Tirzepatida in different doses compared to the adult Smaglutida with type 2 diabetes that does not achieve sufficient control with metformin.

he Ticket It included 1.87 g of participants from the United States, Argentina, Australia, Brazil, Canada, Israel, Mexico and the United Kingdom, randomly distributed in four groups (1: 1: 1: 1) to receive various doses of treatment under study or the competitor’s treatment.

The clinical trial program has been recruited in stage 3 more than 19,000 people with type 2 diabetes In 10 clinical studies, five of which are for global regulatory records.

The National Register of Clinical Experiences (RNEC) contains general information about overcoming clinical trials, and research in the category of “the general name of the product”, the Tirzepatida molecule, in the following league: https: //siipris03.cofepris.gob.mx/resoluciones/consultas/conwebregensayo …

About type 2 diabetes in adults in Mexico

Type 2 diabetes is a The general health problem in Mexico, It affects more than 18.4 million adults, according to ENSANUT 2023. It represents about 90 % of diabetes and they continue to spread due to factors such as stable lifestyle, excess weight and unhealthy food.

This chronic disease is characterized by Insulin resistance High blood sugar levels, which increases the risk of serious complications such as cardiovascular disease, kidney failure and neurological disorder. Despite the high incidence of infection, estimates indicate that about 30 % of cases are not diagnosed, which hinders timely treatment.

Looking at this panorama, it is necessary to enhance health education, enhance healthy habits and ensure access to innovative treatments to help patients to be in the targets of control and improve the quality of their lives.

About diabetes

She was a leader in a pioneer in Diabetes sponsorship since 1923, When the first commercial insulin was presented in the world. Today, its legacy continues through research, innovation and cooperation to improve the lives of people with diabetes and related diseases.

*MVG*